Trial reportBMC psychiatry2026
Efficacy and safety of memantine as adjunctive treatment for manic episodes in bipolar disorder (BD): a randomized, double-blind, placebo-controlled clinical trial.
Trial report in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBipolar disorder (BD) is a chronic and recurrent psychiatric illness, and acute manic episodes are associated with marked functional impairment. Mood stabilizers and antipsychotics remain the mainstay of treatment. Dysregulation of glutamatergic neurotransmission and N-methyl-D-aspartate (NMDA) receptor signaling has been implicated in bipolar disorder (BD), providing a rationale for evaluating memantine as an adjunctive treatment for manic episodes in bipolar I disorder (BD-I).
methodsIn this 6-week randomized, double-blind, placebo-controlled trial, adults aged 18-65 years with DSM-5 BD-I and a current manic episode were allocated 1:1 to adjunctive memantine or placebo, alongside lithium and olanzapine. Memantine was titrated from 5 mg/day to 20 mg/day. Manic symptoms were assessed using the Young Mania Rating Scale (YMRS), with secondary outcomes including Clinical Global Impression (CGI) scales and peripheral inflammatory markers.
resultsSixty-three participants were randomized (memantine n = 31; placebo n = 32). Baseline YMRS scores were comparable between groups. Mean YMRS scores decreased significantly in both groups over time; however, no between-group differences were observed at week 2 (P = 0.674), week 4 (P = 0.778), or week 6 (P = 0.466). At week 6, the magnitude of YMRS reduction did not differ significantly between the memantine and placebo groups. CGI-Severity, CGI-Improvement, and CGI-Efficacy Index scores were also similar between groups at all assessment points (all P > 0.05). Changes in white blood cell count, neutrophil count, lymphocyte count, and neutrophil-to-lymphocyte ratio at week 6 and week 18 showed no statistically significant differences between the memantine and placebo arms in either intention-to-treat or per-protocol analyses.
conclusionsAdjunctive memantine did not provide additional symptomatic or biological benefit beyond lithium and olanzapine in the treatment of acute mania in BD-I. These findings do not support routine use of memantine for acute manic episodes, although further research may be warranted in selected patient subgroups or alternative clinical contexts.
trial registrationIranian Registry of Clinical Trials (IRCT), IRCT20250430065539N1, 30 April 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.